Lotrial D

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lotrial D

Property Description
Active ingredient Enalapril maleate, Hydrochlorothiazide (HCTZ)
Form Tablet (Fixed-dose combination)
Pharmacological class ACE Inhibitor and Diuretic Combination
Common use Management of high blood pressure (hypertension)
Origin Synthetic

Lotrial D is a synthetic, prescription-only medicine defined as a fixed-dose combination drug (FDC) used to manage elevated blood pressure (hypertension). This cardiovascular agent is classified within the high-level pharmacological class of ACE Inhibitor and Diuretic Combinations, a strategy widely recognized for effective therapeutic management. Such enalapril-hydrochlorothiazide combinations are recognized as important components in therapy.

What Type of Medicine is Lotrial D?

Lotrial D is an antihypertensive combination product supplied as a tablet for oral administration. Its FDC identity means it integrates the actions of two drug classes into a single pharmaceutical preparation. Due to its composition, it serves as a common prescription-only medicine for established adult patient groups managing chronic hypertension. The formulation's use in combined therapy is established for its effectiveness.

Composition and Formulation (Enalapril and HCTZ)

The core composition of Lotrial D involves two distinct active ingredients: Enalapril maleate and Hydrochlorothiazide (HCTZ). Enalapril maleate is categorized as a synthetic prodrug within the Angiotensin-Converting Enzyme (ACE) inhibitor class, while Hydrochlorothiazide is a synthetic, sulfonamide-derived thiazide diuretic. The final drug product is formulated with necessary excipients to create the final solid oral dosage form (tablet).

Why are Enalapril and Hydrochlorothiazide Combined?

These active ingredients are combined to achieve a powerful synergistic effect that provides more comprehensive blood pressure lowering than either agent provides alone. The Enalapril component promotes the relaxation of blood vessels (vasodilation), and the Hydrochlorothiazide component helps the body manage fluid volume by increasing salt and water elimination (diuresis). This dual-action strategy, clinically recognized for its effective blood pressure control, helps stabilize blood pressure levels and relieve the strain on the entire cardiovascular system.

Regulatory References

  1. Model List of Essential Medicines
  2. National Institutes of Health

What side effects are possible with Lotrial D?

Possible side effects and safety information

The official safety profile for the Enalapril maleate and Hydrochlorothiazide combination (Lotrial D) organizes possible adverse reactions by frequency and the body system affected, according to government regulatory standards.

Frequency-Classified Adverse Reactions

The most frequently documented effects, classified as Common (ge 1/100 to < 1/10) in regulatory documents, include dizziness, headache, cough, fatigue, and nausea. Effects classified as Uncommon (ge 1/1,000 to < 1/100) may include palpitations, pancreatitis, vertigo, and various skin reactions. Rare (ge 1/10,000 to < 1/1,000) documented reactions include agranulocytosis and hepatic failure.

Adverse effects are also categorized across several System-Organ Classes, including the Nervous System (dizziness, headache), Respiratory System (cough), Gastrointestinal Disorders (nausea, abdominal pain), and Blood and Lymphatic System (anaemia, leucopenia).

Serious Safety Considerations

The official prescribing information highlights the potential for serious adverse reactions, such as angioedema (swelling of the face, tongue, or larynx) and rare occurrences of hepatic failure or severe renal failure. The regulatory profile notes that hypotension (low blood pressure) is most likely to manifest following the initial dose or during dose escalation.

Safety restrictions mean the medicine is contraindicated in patients with severe renal impairment (anuria or creatinine clearance le 30 frac mL min) and during the second and third trimesters of pregnancy. It is also contraindicated in individuals with a history of angioedema related to previous ACE inhibitor use, and caution is required in patients with severe hepatic impairment.

Overdose and Emergency Response

The official regulatory profile for Lotrial D overdose centers on severe, life-threatening complications related to the drug’s exaggerated effects. The most critical documented manifestation is profound hypotension (severely low blood pressure), often leading to syncope (fainting), dizziness, and confusion. Symptoms of severe fluid and electrolyte depletion, such as intense thirst and muscle cramps, are also officially documented.

Immediate medical assistance is required for any suspected overdose. Emergency services must be contacted if the affected individual is unresponsive, seizing, or has trouble breathing. Regulator documents emphasize that Angioedema (swelling of the face or throat) is a severe complication that mandates urgent attention.

No specific chemical antidote is known for this combination. Management, as described in official prescribing information, is entirely symptomatic and supportive. This includes the required procedure of volume expansion using intravenous fluids to address severe hypotension. Continuous hospital monitoring is mandated, involving the use of ECG (heart tracing) and frequent blood and urine tests to correct critical electrolyte imbalances and assess renal function. Individuals with pre-existing severe heart failure or renal impairment are noted to have increased risk for severe outcomes.

Therapeutic Uses of Lotrial D

What Lotrial D Treats: Main Uses and Benefits

Lotrial D provides supportive therapeutic benefit and is applied across domains where additional symptomatic support is needed, including the management of high blood pressure (hypertension). It is relevant in contexts involving heightened systemic burden. The combination product is commonly used for the symptomatic management of hypertension (high blood pressure). This application is used for managing symptoms often related to heightened physiological activity and creating noticeable physiological strain.


Relief for Symptoms That Interfere with Daily Functioning

Lotrial D is applied across domains where additional symptomatic support is needed. It is used for managing symptoms that interfere with daily functioning and create noticeable physiological strain. It is relevant when symptoms become temporarily overwhelming. The medication is commonly used across conditions involving episodic or fluctuating manifestations, often when short-term symptomatic assistance is appropriate.

“It is relevant for easing distress and supporting the patient during difficult episodes.”


Key Use: Addressing Noticeable Physiological Strain


The combination is applicable within clinical settings that involve acute or unstable symptom patterns, relevant when supportive symptom management is appropriate. It contributes to improved comfort during periods of heightened symptoms and provides support that helps ease the overall symptom burden.

Eligibility and Restrictions for Use

Eligibility for Lotrial D: Official Regulatory Rules

Lotrial D is officially labeled for use in Adults with essential hypertension. However, eligibility is strictly defined by regulatory contraindications and restrictions based on patient status, comorbidity, and age.

Populations Who Must Not Use Lotrial D (Contraindicated):

  • Patients with a history of Angioedema (swelling of the face, tongue, or throat) related to previous ACE inhibitor use, or those with hereditary angioedema.
  • Individuals with known hypersensitivity to enalapril, hydrochlorothiazide, or any sulfonamide-derived drug.
  • Patients with Anuria, Severe Renal Impairment (CrCl le 30 mL/min), or Severe Hepatic Impairment.
  • Use is contraindicated during the second and third trimesters of pregnancy.

Age and Specific Restrictions:

  • Pediatrics (<18 years): Use is not recommended; safety and efficacy have not been established by regulatory bodies.
  • Pregnancy/Lactation: Use is not recommended in the first trimester or during lactation. The medicine is contraindicated with Aliskiren in patients with diabetes or renal impairment, and must be avoided within 36 hours of switching to or from Sacubitril/Valsartan.

What should I know about interactions with other medicines?

The official interaction profile for Lotrial D, reflecting its Enalapril (ACE inhibitor) and Hydrochlorothiazide (diuretic) components, is defined by specific restrictions detailed in regulatory documents.

Contraindicated Combinations and Timing Rules

Formal regulatory labels establish a Contraindicated Combination with the Sacubitril/Valsartan combination, which is strictly prohibited. Use requires a mandatory 36-hour separation period before initiating or after discontinuing Lotrial D. Furthermore, co-administration with Aliskiren-containing drugs is prohibited in patients with Diabetes Mellitus or existing moderate to severe renal impairment.

Pharmacodynamic and Exposure Interactions

Documented Pharmacodynamic Interactions include an increased risk of hyperkalemia when Lotrial D is co-administered with Potassium supplements or Potassium-sparing diuretics. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may reduce the antihypertensive effect and increase the risk of renal impairment. The co-administration of mTOR inhibitors is officially noted for increasing the risk of angioedema.

A key Pharmacokinetic Interaction involves Lithium, where Lotrial D causes the reduced renal clearance of Lithium, raising the risk of toxicity. Separately, Cholestyramine and Colestipol resins officially cause a significant reduction in the absorption of the Hydrochlorothiazide component. Alcohol is also listed as a substance that potentiates the risk of orthostatic hypotension.

Mechanism of Action

Lotrial D is a fixed-dose combination containing enalapril maleate and hydrochlorothiazide, which exert distinct and complementary pharmacodynamic actions. Enalapril, a prodrug, undergoes hydrolysis to its active metabolite, enalaprilat, a competitive inhibitor of angiotensin-converting enzyme (ACE). ACE catalyzes the conversion of angiotensin I to angiotensin II. Enalaprilat's inhibition of ACE reduces plasma angiotensin II concentration, which diminishes vasoconstrictor activity and lowers aldosterone secretion from the adrenal cortex. This decrease in angiotensin II and subsequent aldosterone also disrupts the negative feedback loop on renin release, resulting in increased plasma renin activity. The decreased angiotensin II leads to system-level vasodilation, reducing total peripheral resistance.

Hydrochlorothiazide, a thiazide-class diuretic, acts on the renal distal convoluted tubule. It functions as an inhibitor of the Na^+/ Cl^- symporter, also known as the solute carrier family 12 member 3 (SLC12A3). This action blocks the reabsorption of sodium and chloride ions from the tubular lumen, which results in increased urinary excretion of water and electrolytes, including Na^+ and Cl^-. This augmented natriuresis and diuresis modulates total body fluid volume and contributes to systemic hemodynamic changes.

Dosage and Administration Information

How to Use Lotrial D

Lotrial D is a fixed-dose combination product intended for the management of hypertension, and its administration follows specific rules outlined in official prescribing information.


Official Administration Protocol

The medicine is designed for oral administration as a tablet and is taken once daily. This fixed combination is not indicated for use as initial therapy for high blood pressure. Rather, its use is strictly reserved for adult patients whose dosage has already been stabilized and controlled by the same proportions of the individual components, Enalapril and Hydrochlorothiazide (HCTZ), administered separately.

Administration is flexible concerning meals; the tablet may be taken with or without food. To ensure a consistent effect, the daily dose should be taken at approximately the same time each day.


Dosing and Procedural Constraints

The usual adult maintenance dose is one tablet once daily, although available strengths vary. If a dose is missed, patients are instructed to skip the missed dose if it is near the time for the next scheduled dose, and not take a double dose to compensate.

Specific constraints apply to patient populations based on physiological status. The combination product is not recommended for use in patients with severe renal impairment, defined as a creatinine clearance (CrCl) of le 30 mL/min. Furthermore, its safety and efficacy have not been established for pediatric patients under the age of 18.

Recent Clinical Evidence

Research evidence / Overview of studies

Research has evaluated whether the drug has been proposed to influence central pain signaling. Initial studies have explored whether this action may be relevant to changes in self-reported chronic discomfort. Studies have included evaluations of the compound in populations with neuropathic pain. Some research has compared the drug's initial time-to-onset of potential effect with other studied compounds.


Efficacy in Neuropathic Pain

A significant portion of the evidence for this compound comes from randomized controlled trials (RCTs) focusing on different forms of chronic pain, especially pain related to nerve damage.

  • One large-scale RCT reported that participants using the drug experienced an average 40% change in a measure of daily function as an outcome. This study followed 500 adults over a 12-week period.
  • Other studies have explored whether the compound is associated with improved sleep quality in participants experiencing chronic pain. Findings have been mixed, with some showing an association with longer sleep duration, and others reporting no statistically significant difference.
  • Research has examined the co-administration of the compound with Drug B to study measured outcomes.

Safety and Tolerability Profile

Studies note that the drug has been evaluated in adults. Research on individuals with severe liver or kidney issues is limited or included specific caveats regarding safety for these groups.

Studies have investigated whether long-term administration is associated with a change in the frequency of pain episodes. The findings from these studies were not sufficient to establish a clear causal relationship or consistent therapeutic effect.

Key Studies & References Chronic Pain (NICE Guideline NG193): Management of Chronic Primary Pain

Frequently Asked Questions (FAQ)

Common questions about Lotrial D (FAQ)


Q: Is Lotrial D a type of blood pressure medicine?

Official regulatory documents classify Lotrial D as an antihypertensive medicine. Its primary indicated use is for the long-term management of high blood pressure, also known as hypertension.


Q: How is Lotrial D different from just taking Lotrial?

Lotrial D is a fixed-dose combination (FDC) that contains two active ingredients: enalapril (the component often referred to as Lotrial) and hydrochlorothiazide. The FDC combines an ACE inhibitor and a diuretic. The combination is noted in official documents for its intended dual mechanism of action, which contributes to the lowering of blood pressure.


Q: Why do some people need the 'D' version of this medication?

Regulatory documents indicate that this combination medicine is generally reserved for patients whose blood pressure was not adequately controlled with the single component alone. It is also used for patients who have already been stabilized on the same proportional dosages of the individual components, enalapril and hydrochlorothiazide, taken separately.


Q: How long does it usually take to notice the effects of Lotrial D?

Information on the components indicates that the antihypertensive activity for enalapril can begin as early as one hour after taking a dose. The peak effect—when the blood pressure reduction is greatest—is typically seen within four to six hours. The effects of the prescribed dose have been shown to maintain for at least 24 hours.


Q: What are the most commonly reported side effects of Lotrial D?

The most frequently documented effects reported in regulatory documents, categorized as Common, include dizziness, headache, cough, fatigue, and nausea. A full description of all documented adverse effects is contained within the official product prescribing information.


Q: Are headaches a common side effect of taking Lotrial D?

Yes, official safety information lists headache as one of the most frequently documented adverse effects. This effect is classified as Common (occurring in ge 1/100 to < 1/10 patients) in regulatory documents.


Q: Is it normal to have to urinate more often when starting Lotrial D?

The 'D' component, hydrochlorothiazide, is a diuretic, which means it is intended to increase the flow of urine to remove excess salt and water. This diuretic action may result in a recognized need to urinate more often.


Q: Is a rash a sign of a serious side effect with Lotrial D?

Official safety information notes the potential for various skin reactions. While a common rash may be categorized as an Uncommon effect, a rash may also be an initial symptom of a very serious allergic reaction, such as angioedema (swelling) or a severe skin condition. More severe reactions are listed in the safety profile.


Q: Is Lotrial D appropriate for people with diabetes?

Regulatory documents indicate that the use of Lotrial D is subject to a strict regulatory contraindication when combined with aliskiren-containing drugs in patients who also have diabetes mellitus. Furthermore, regulatory documents list diabetes as a medical condition where specific caution or monitoring may be indicated during use.


Q: Does Lotrial D have a generic or off-brand version available?

Yes, the combination of its two active ingredients—enalapril and hydrochlorothiazide—is widely available as a generic prescription medication.


Q: Is Lotrial D used for anything besides high blood pressure?

Official regulatory labels strictly indicate that this medicine is used only for the management of high blood pressure, or hypertension, in adults.


Q: Can Lotrial D affect cholesterol levels?

Regulatory documents note that the diuretic component, hydrochlorothiazide, has been associated with potential increases in total cholesterol and triglyceride levels. Regulatory documents indicate that monitoring of these levels may be performed during treatment.


Q: Is weight gain a potential side effect listed for Lotrial D?

Unexplained weight gain or swelling (edema) in the hands, feet, or ankles is listed in official warning information as a symptom that requires assessment. This is noted as a potential sign of underlying kidney issues.


Q: What is the difference between an ACE inhibitor and a diuretic?

These are two different classes of medication combined in Lotrial D. The ACE inhibitor component (enalapril) works by relaxing blood vessels to lower blood pressure. The diuretic component (hydrochlorothiazide) works in the kidneys to increase the removal of unneeded water and salt from the body via urine.


Q: Can Lotrial D affect your mood or energy levels?

Official safety information lists fatigue, or tiredness, as a common side effect of the medicine. Mood changes or feeling very tired are also noted as potential signs of an electrolyte imbalance, which is a known risk associated with the diuretic component.


Q: Does this medication require regular blood tests?

Regulatory documents indicate that blood tests may be performed before and periodically during treatment. This monitoring is typically done to check kidney function, liver function, and to ensure electrolyte levels (such as potassium) remain balanced.


Q: What kind of monitoring is generally suggested while taking Lotrial D?

Monitoring suggested in product information typically includes periodic checks of kidney function, liver enzymes, and serum electrolytes. Additionally, cholesterol, triglycerides, and white blood cell counts may be checked, depending on the patient’s status.


Q: What is the half-life of the drug components in Lotrial D, as per regulatory documents?

Regulatory documents provide the half-life for the active components. The effective half-life for the active metabolite, enalaprilat, is approximately 11 hours. The plasma half-life of the other component, hydrochlorothiazide, is officially listed as ranging between 5.6 and 14.8 hours.


Q: Can I take Lotrial D if I have a history of gout?

Official information lists a history of gout as a condition where the medicine should be used with caution, as it may potentially make the condition worse. It is not an absolute contraindication, but it is an important safety consideration noted in the product information.


Q: Can Lotrial D make you feel dizzy or lightheaded?

Dizziness is listed as a common side effect of the medicine. Official patient information indicates that lightheadedness may occur, especially when standing up. This is noted as a potential sign of low blood pressure (hypotension), which is most likely to occur early in the course of therapy.


Q: Are there different strengths or dosages of Lotrial D tablets?

Yes, Lotrial D (enalapril/hydrochlorothiazide) is supplied in different tablet strengths, such as the 5 mg/12.5 mg and 10 mg/25 mg formulations. The available strength is determined by the healthcare provider to match the patient's specific needs.

How should Lotrial D be stored and disposed of?

Storage and Disposal Requirements for Lotrial D

The storage and disposal of Lotrial D (enalapril maleate/hydrochlorothiazide) must follow specific regulatory guidelines to maintain product integrity and ensure environmental safety.

Official Storage Conditions

Condition Requirement
Temperature Store at controlled room temperature (e.g., 15 C to 30 C).
Protection Keep away from excess heat, moisture, and direct light.
Container Keep in the original container and ensure the lid is tightly closed.
Prohibition The product must be kept from freezing.

Handling and Disposal

It is mandatory to store the medication out of the reach of children. Unused or expired medicine should not be kept. For disposal, official instructions prohibit throwing the tablets into wastewater (sink or toilet) or household trash. Patients must consult a healthcare professional or local waste disposal company for proper, environmentally safe discarding methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lotrial D found in:

A-Z Index: